ReNeuron Group (RNUGF) Stock Price, News & Analysis

Company Overview

ReNeuron Group plc is a clinical‐stage biotechnology company focused on the development and commercialization of stem cell‐based therapies for serious medical conditions. The company leverages a proprietary human neural stem cell platform (CTX) to address neurological deficits after stroke, with its lead candidate having completed Phase II clinical studies. ReNeuron has expanded its pipeline to include a human retinal progenitor cell therapy (hRPC) for the treatment of retinitis pigmentosa and is investigating exosome-based products for tissue repair and wound healing.

Founded in the late 1990s and headquartered in the United Kingdom, ReNeuron has established Good Manufacturing Practice (GMP) facilities to support the production of its cell therapy candidates. The company’s research and development activities are primarily conducted in the U.K., while its clinical programs involve collaboration with research institutions and hospitals in Europe and North America. This international footprint enables ReNeuron to advance multiple programs simultaneously across different regulatory environments.

ReNeuron’s proprietary technologies encompass both stem cell and exosome platforms, offering potential versatility in treating a range of indications beyond its lead programs. In addition to neurological and ophthalmological applications, the company is exploring ways to apply its exosome knowledge to regenerative medicine and drug delivery. By combining cell biology expertise with scalable manufacturing processes, ReNeuron aims to position itself as a leader in next-generation cell therapies.

The company is led by a team of scientists and industry veterans with extensive experience in cell therapy development, clinical research and regulatory affairs. ReNeuron’s board and executive management draw on decades of expertise in biotechnology to guide strategic partnerships, fund-raising activities and clinical trial design. As a dual-listed entity on the London Stock Exchange and the OTC Markets (OTCMKTS:RNUGF), ReNeuron continues to advance toward potential regulatory approvals and commercialization milestones in targeted therapeutic areas.

Key Stats

• Today's Range: N/A
• 50-Day Range: N/A
• 52-Week Range: N/A
• Volume: N/A
• Average Volume: N/A
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Company Calendar

• Today: 6/12/2026
• Fiscal Year End: 3/31/2027

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: MED - DRUGS
• Sub-Industry: N/A
• Current Symbol: OTCMKTS:RNUGF
• Previous Symbol: NASDAQ:RNUGF
• CIK: N/A
• Web: www.reneuron.com
• Phone: 44-20-3819-8400
• Fax: N/A
• Employees: 26
• Year Founded: 1997

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: -0.64